DeğerQ4, 24Q4, 25TTMSelling/general/admin expenses———Research & development———Faaliyet karı———Faaliyet Dışı Gelir, Toplam———Faiz gideri (aktifleştirilmiş faiz düşüldükten sonra)———Faaliyet Dışı Gelir (Faiz Giderleri Hariç)———Olağandışı gelir/gider———Vergi öncesi kar———Kazançlardaki özsermayeler———Vergiler———Kontrol gücü olmayan/azınlık payları———Vergi sonrası diğer gelirler/giderler———Durdurulan faaliyetler öncesi net kar———Durdurulan faaliyetler———Net kar———Seyreltme ayarlaması———İmtiyazlı temettüler———Adi hisse senedi sahiplerine düşen seyreltilmiş net kar———Temel hisse başına kazanç (Temel EPS)———Seyreltilmiş hisse başına kazanç (Seyreltilmiş EPS)———Dolaşımdaki ortalama adi hisse sayısı———Seyreltilmiş hisse sayısı———FAVÖK———FVÖK———Gelir maliyeti———Satılan malların diğer maliyeti———Depreciation & amortization (cash flow)———
GSK plc American Depositary Shares (Each representing two Ordin
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost.